Login

News& Outreach*

News from mainstream media*

Our RISEbrain partners have been published and featured in top media outlets and conferences.

30/08/2023

  • Manuel Valiente

NEWS

Un estudio descubre que los tumores cerebrales ‘hackean’ la comunicación entre neuronas

Telemadrid. Video.

Read more

26/06/2023

  • Manuel Valiente

News

Neurociencia del cáncer: así secuestran los tumores el sistema nervioso para crecer más rápido

El País

Read more
  • Serap Aksu

Public outreach activities

Closing women’s health inequality gaps

Read more
  • Serap Aksu

News

Nanotechnology: a portable device against cervical cancer

Read more
  • Serap Aksu

Grants

EMBO Installation Grant, TUBITAK National Outstanding Researchers Program

  • Serap Aksu

Awards

AXA research fund fellowship, ETH postdoctoral fellowship

2018

  • Serap Aksu

Scientific activities

A portable device against cervical cancer

Read more

2023

  • Marc Schmitz

Clinical studies (Immune monitoring performed by Schmitz group)

A phase II single arm clinical trial of a tailored immunotherapy approach with nivolumab in subjects with metastatic or advanced transitional cell carcinoma

2023

  • Marc Schmitz

Clinical studies (Immune monitoring performed by Schmitz group)

A phase II single arm clinical trial of a tailored immunotherapy approach with nivolumab in subjects with metastatic or advanced renal cell carcinoma

2023

  • Marc Schmitz

Characterization of the immune architecture and immunomodulatory capabilities of melanoma-derived brain metastases

Funding Organisation: Federal Ministry of Education and Research

2023

  • Marc Schmitz

Grants

SaxoCell: Development of theranostic target molecules for diagnosis and therapy

Funding Organisation: Federal Ministry of Education and Research

2023

  • Luca Bertero

Grant for internationalization

Molecular dissection of ovarian cancer brain metastasis microenvironment through spatial transcriptomics

Project partners: Pathology unit, Department of Medical Sciences, University of Turin, Italy and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK

Amount: 55.481,46€

2023

  • Luca Bertero

Clinical studies

SILMET

A controlled, randomized, double-blind clinical trial to evaluate the efficacy of SILbinin versus placebo to prevent recurrence after surgical resection of a single brain METastasis from non-small cell lung carcinoma or breast carcinoma

10/2013

  • Hind Medyouf

Invited Speaker

European Macrophage and Dendritic cell society (EMDS) meeting

VIB Ghent, Belgium

06/2023

  • Hind Medyouf

Invited speaker

European Hematology Association Annual meeting

Frankfurt, Germany

02/2023

  • Hind Medyouf

Delegation member

EMBO India Research Partnership Tour

India

Read more